TGA suspends Australia's only at-home STI test over false negatives

What just happened

The Therapeutic Goods Administration has suspended Australia’s only at-home test for chlamydia and gonorrhoea for six months. The device in question is the TouchBio chlamydia and gonorrhoea self-test, which was designed for self-collection by females and had been available since it was approved and launched in 2024.

The suspension runs until 17 December 2026. The basis for it is a finding from independent laboratory testing that identified performance concerns — specifically, that the device produces false negative results. The TGA’s language in the suspension notice is direct: false negative results may lead to missed detection of infection, delays in diagnosis and treatment, and ongoing transmission of chlamydia and gonorrhoea.

The TGA has stated explicitly that “a negative result from the device does not exclude infection” — and has advised that the test should not replace assessment by a medical practitioner.

The manufacturer is undertaking additional work to demonstrate the device can reliably detect infections at the required concentrations. Until that work satisfies the TGA’s requirements, the device cannot be supplied.

---

The both-and

Why this matters — and why it is not just a product-recall story

Chlamydia and gonorrhoea are among the most commonly notified infectious diseases in Australia. Chlamydia consistently leads the sexually transmitted infection (STI) notification tables year on year. Both infections carry significant clinical consequences if missed and untreated — including pelvic inflammatory disease, fallopian tube damage, and downstream effects on fertility for women — and both are frequently asymptomatic, which means testing is the only reliable way to know your status.

The appeal of an at-home self-test is obvious: it removes the GP or clinic visit as a barrier to testing. For people who find sexual health conversations uncomfortable, who are time-poor, or who live in areas with limited access to sexual health services, a device that could be used at home and provided an answer within minutes represented a genuine access improvement.

The problem is that an at-home test that produces false negatives is not just clinically neutral — it is actively harmful. A person who tests negative but is actually infected may delay treatment indefinitely, believing they are clear. Their partners may not be tested. An asymptomatic infection that would have been caught and treated may instead progress or be passed on. The TGA’s suspension reflects this logic: a test with this level of performance failure is worse than not testing.

The underlying access problem is real and unchanged

The suspension does not solve the problem the TouchBio test was trying to address. STI testing in Australia is not uniformly easy to access. GP visits take time and may feel awkward. Sexual health clinics exist in metropolitan centres but are not universally accessible. Stigma around STI testing is still a barrier for some people, particularly in smaller communities where privacy feels harder to maintain.

The most reliable testing pathway — standard pathology through a GP clinic or sexual health service — remains available, highly accurate, and in many cases eligible for Medicare. Urine nucleic acid amplification tests (NAATs/PCR) for chlamydia and gonorrhoea have very high sensitivity when processed in an accredited laboratory. The issue has never been the quality of laboratory testing; it has been access to and uptake of testing in populations where infection rates are highest.

The TouchBio suspension means that gap reopens for people who were using the device as their primary testing method. Alternative at-home sampling options — self-collected urine and swab kits sent to a pathology laboratory — are available through some clinics and online sexual health services. These differ from the suspended device in one crucial respect: the sample is collected at home, but it is processed in a proper laboratory with full analytical validation.

What GPs should consider

The TGA has specifically urged medical professionals to consider appropriate follow-up and confirmatory testing for individuals at risk who may have used this device. In practice, this is likely to surface in two ways: patients who present having already tested negative on the device and are seeking reassurance, and patients who are asymptomatic and may not have connected a recent negative test to the current news.

The key message for clinical conversations is that the suspension applies to this specific device — not to STI testing in general, and not to any patient who has concerns about their own infection status. Standard pathology testing remains available and reliable.

---

My two cents

The TGA acted correctly here. A diagnostic device that produces false negatives in independent testing should not be on the market, and the six-month suspension gives the manufacturer time to either fix the problem or withdraw the product — while removing an unreliable test from the hands of people who need accurate results.

For anyone who used the TouchBio self-test and received a negative result — particularly in the past six to twelve months — this week’s news is a prompt to check in with a GP about follow-up testing. Not with alarm, but with the recognition that the result you received may not have been reliable.

STI testing is not complicated or expensive in Australia, and it does not require symptoms to be worthwhile. It requires access — and for most people, that access is a GP appointment away.

---

Verdict: yes — worth knowing about.

---

Sources cited

1. RACGP newsGP — TGA suspends chlamydia and gonorrhoea self test (July 2026). https://www1.racgp.org.au/newsgp/clinical/tga-suspends-chlamydia-and-gonorrhoea-self-test
2. TGA — Performance concerns identified in TouchBio chlamydia and gonorrhoea self-test. https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/performance-concerns-identified-touchbio-chlamydia-and-gonorrhoea-self-test